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Introduction {#jdi12681-sec-0005}
============

Gut--brain communication, the so‐called enteric nervous system, maintains complex homeostatic body states including energy homeostasis[1](#jdi12681-bib-0001){ref-type="ref"}, [2](#jdi12681-bib-0002){ref-type="ref"}. Enteroendocrine cells (EECs) in the gastrointestinal (GI) tract secrete a large number of peptide hormones that form a homologous family; these cells are traditionally classified by immunocytochemistry into at least 10 different cell types[3](#jdi12681-bib-0003){ref-type="ref"}. More than 100 kinds of gut hormones secreted from EECs have been identified; therefore, the gut is recognized as the largest endocrine organ in the body[4](#jdi12681-bib-0004){ref-type="ref"}. However, analysis of EECs has been difficult, because they comprise \<1% of all gut epithelial cells, and are not concentrated like other endocrine organs.

Glucagon‐like peptide‐1 (GLP‐1) is a 31‐amino‐acid polypeptide hormone produced in enteroendocrine L cells located mainly in the distal part of the GI tract[5](#jdi12681-bib-0005){ref-type="ref"}. GLP‐1 is one of the major 'incretins' that potentiates a greater and more persistent plasma insulin increase with an oral glucose load than it does with intravenous glucose infusion[6](#jdi12681-bib-0006){ref-type="ref"}. GLP‐1 also shows extrapancreatic effects in the cardiovascular system, GI tract and central nervous system[5](#jdi12681-bib-0005){ref-type="ref"}, [6](#jdi12681-bib-0006){ref-type="ref"}, [7](#jdi12681-bib-0007){ref-type="ref"}. Therefore, GLP‐1 has been targeted in clinical applications in patients with type 2 diabetes by dipeptidyl peptidase‐4 inhibitors, which delay degradation of endogenous GLP‐1, and GLP‐1 receptor mimetics[6](#jdi12681-bib-0006){ref-type="ref"}, [7](#jdi12681-bib-0007){ref-type="ref"}. Furthermore, the increase in plasma GLP‐1 levels is beneficial in patients with type 2 diabetes. Another strategy for GLP‐1 treatment stimulates the release of GLP‐1 from L cells[8](#jdi12681-bib-0008){ref-type="ref"}.

Different EECs are developed from close cell lineages, thus, coexistence of several peptide hormones have been distinguished[9](#jdi12681-bib-0009){ref-type="ref"}. Proglucagon protein is produced from the proglucagon (*Gcg*) gene in L cells. Prohormone convertase (PC) 1/3 cleaves proglucagon into glicentin‐specific peptide, GLP‐1 and GLP‐2 in an L‐cell‐specific manner[5](#jdi12681-bib-0005){ref-type="ref"}, [10](#jdi12681-bib-0010){ref-type="ref"}. Furthermore, L cells have been shown to co‐express several related intestinal hormones, such as peptide YY (PYY) and gastric inhibitory polypeptide (GIP; also called glucose‐dependent insulinotropic polypeptide)[11](#jdi12681-bib-0011){ref-type="ref"}, [12](#jdi12681-bib-0012){ref-type="ref"}, [13](#jdi12681-bib-0013){ref-type="ref"}. Using mice lacking transcription factor genes, such as *paired‐box domain transcription factor* (*Pax*) *4*,*Pax6* and *pancreatic duodenal homeobox 1* (*Pdx1*), several groups of transcription factors have been suggested to have key roles in L cells[14](#jdi12681-bib-0014){ref-type="ref"}, [15](#jdi12681-bib-0015){ref-type="ref"}, [16](#jdi12681-bib-0016){ref-type="ref"}.

L cells are located broadly from the upper intestine (UI) to the colon; however, little is known about the L cell distribution throughout the GI tract. Recently, transgenic mouse models expressing green fluorescent protein (GFP) variants under the control of promoters of gut peptide precursors have been generated, enabling EEC analysis[17](#jdi12681-bib-0017){ref-type="ref"}, [18](#jdi12681-bib-0018){ref-type="ref"}. However, these modified mice are altered through the use of transgenic engineering techniques that represent the gain‐of‐function approach. In the present study, we used previously established glucagon‐GFP knock‐in (Gcg‐GFP) mice that express GFP driven by the native *proglucagon* promoter[19](#jdi12681-bib-0019){ref-type="ref"}, to analyze and purify L cells as GFP‐positive (GFP\[+\]) cells by flow cytometry. The purpose of the present study was to elucidate the differences between primary murine L cells in the UI, the lower small intestine (LI) and the colon, with the aim of helping to establish a new therapeutic approach for increasing GLP‐1 secretion from L cells in patients with type 2 diabetes.

Methods {#jdi12681-sec-0006}
=======

Animals {#jdi12681-sec-0007}
-------

Gcg‐GFP heterozygous (Gcg^gfp/+^) mice generated as reported previously[19](#jdi12681-bib-0019){ref-type="ref"} were backcrossed with the C57BL/6J strain for more than 10 generations. The blood glucose levels, serum insulin levels, plasma GLP‐1 levels and L‐cell population in the Gcg^gfp/+^ mice were not altered compared with those in wild‐type mice, as previously described (data not shown)[19](#jdi12681-bib-0019){ref-type="ref"}. We used 7--16‐week‐old heteromutant male mice to analyze GFP(+) and GFP‐negative (GFP\[−\]) cells as L cells and non‐L cells, respectively. The mice were housed in an air‐controlled (25°C) room with a dark--light cycle of 10:14 h. This study was carried out in strict accordance with Directive 2010/63/EU for animal experiments. Animal care and procedures were approved by the Kyoto University Animal Care Committee. All efforts were made to minimize the suffering of the animals.

Histological and quantitative analyses of the gut {#jdi12681-sec-0008}
-------------------------------------------------

Mice were killed by cervical dislocation and the GI tract was quickly removed. The small intestine was divided into two portions at the middle position, and the oral and rectal portions were defined as the UI and LI, respectively. Samples were fixed in Bouin\'s solution and embedded in paraffin as previously described[20](#jdi12681-bib-0020){ref-type="ref"}, [21](#jdi12681-bib-0021){ref-type="ref"}. In brief, paraffin sections were blocked for 15 min in 3% bovine serum albumin at room temperature, and then incubated with a mouse monoclonal anti‐GFP antibody (sc‐9996, 1:100; Santa Cruz Biotechnology Inc., Santa Cruz, California, USA) as the primary antibody overnight at 4°C. According to the manufacturer\'s information, this antibody was raised against amino acids 1--238 representing the full length GFP of *Aequorea victoria*. The sections were then incubated with a goat anti‐mouse secondary antibody (A‐11001, 1:200; Life Technologies, Tokyo, Japan) for 1 h at room temperature. Images were taken by a fluorescent microscope with a BZ‐X700 system (KEYENCE Corporation, Osaka, Japan). A total of 50 representative crypt--villus units from each slide were randomly selected only when there was a complete longitudinal section of a villus and its associated crypt. The length (μm) of the crypt--villus units was measured from the tip to the base. The number of GFP(+) cells was counted in the 50 representative crypt--villus units. The densities were expressed as the number of GFP(+) cells per micrometer length of a crypt--villus unit (cell/μm; *n* = 4--5).

Isolation and collection of L cells from mouse intestinal epithelium {#jdi12681-sec-0009}
--------------------------------------------------------------------

The isolation of L cells from mouse intestinal epithelium has been described previously[21](#jdi12681-bib-0021){ref-type="ref"}. In brief, the intestine was injected with Hank\'s balanced salt solution containing 0.5 mg/mL collagenase P (Roche Diagnostics, Manheim, Germany), and incubated at 37°C for 10 min in Krebs--Ringer bicarbonate buffer. The digested intestinal epithelium was collected and rinsed. Next, samples were filtered with a cell strainer (352340, BD Falcon cell strainer; Becton, Dickinson and Company, Franklin Lakes, New Jersey, USA). GFP(+) and GFP(−) cells from the intestinal epithelium were analyzed and sorted as L cells and non‐L cells, respectively, using the BD FACS Aria™ flow cytometer (Becton Dickinson and Company). Sorted cells were collected into the buffer.

Measurement of GLP‐1 and GIP content in the sorted L cells {#jdi12681-sec-0010}
----------------------------------------------------------

GFP(+) and GFP(−) cells (5,000 per segment) were sorted in 0.1 N HCl lysis buffer. The GLP‐1 and GIP content in the cell extracts were assayed using a total GLP‐1 enzyme‐linked immunosorbent assay kit (Meso Scale Discovery, Gaithersburg, Maryland, USA) and a total GIP enzyme‐linked immunosorbent assay kit (Merck Millipore, Darmstadt, Germany), respectively. Protein concentration was determined using the Bio‐Rad Protein Assay Kit (Bio‐Rad Laboratories, Inc., Hercules, California, USA).

Assay of GLP‐1 secretion by the sorted L cells {#jdi12681-sec-0011}
----------------------------------------------

A total of 5,000 GFP(+) cells were sorted in 5.5 mmol/L glucose Dulbecco\'s modified Eagle\'s medium from the UI and the LI of Gcg^gfp/+^ mice after an overnight fast (16 h). After 15 min of incubation with 25 mmol/L glucose Dulbecco\'s modified Eagle\'s medium at 37°C, all samples were centrifuged for 3 min. The supernatants were collected and GLP‐1 levels were assayed using a total GLP‐1 enzyme‐linked immunosorbent assay kit.

Ribonucleic acid extraction and quantitative reverse transcription polymerase chain reaction {#jdi12681-sec-0012}
--------------------------------------------------------------------------------------------

Total ribonucleic acid (RNA) was extracted with the PicoPure RNA isolation kit (Applied Biosystems, Inc., Alameda, California, USA) from 2,000 sorted cells and treated with deoxyribonuclease (Qiagen Inc., Valencia, California, USA). Complement deoxyribonucleic acid was prepared by reverse transcriptase (Invitrogen, Carlsbad, California, USA) with an oligo(dT) primer (Invitrogen). The messenger RNA (mRNA) levels were measured in a total volume of 20 μL by SYBR Green‐based reverse transcription polymerase chain reaction using the StepOnePlus™ Real‐Time PCR System (Applied Biosystems Inc., Foster City, California, USA). Polymerase chain reaction analysis was carried out with 0.2 μmol/L of the primers listed in Table [S1](#jdi12681-sup-0001){ref-type="supplementary-material"}. Thermal cycling conditions were denatured at 95°C for 10 min followed by 50 cycles of 95°C for 15 s and 60°C for 1 min. Melting curve dynamics and the absence of primer dimers were confirmed. *Peptidylprolyl isomerase A* was used as the internal control for normalization. All data are shown using the Δcycle threshold (ΔCT) method (CT \[internal control\] − CT \[target gene\]).

Statistical analysis {#jdi12681-sec-0013}
--------------------

The results are given as mean ± standard error of the mean (*n* = number of mice). Statistical significance was determined using paired and unpaired Student\'s *t*‐test and analysis of variance with the Games--Howell test. *P* \< 0.05 was considered statistically significant.

Results {#jdi12681-sec-0014}
=======

Density and quality of L cells in Gcg^gfp/+^ mice {#jdi12681-sec-0015}
-------------------------------------------------

Gcg^gfp/+^ mice enabled the identification of L cells and non‐L cells as GFP(+) cells and GFP(−) cells, respectively (Figure [1](#jdi12681-fig-0001){ref-type="fig"}a). L cells were observed in the UI, LI and colon of Gcg^gfp/+^ mice. The length of the crypt--villus units of the LI (319.0 ±17.5 μm), and the colon (194.3 ± 5.7 μm) was significantly shorter than that of the UI (583.6 ± 19.6 μm; Figure [1](#jdi12681-fig-0001){ref-type="fig"}b). The number of L cells per crypt--villus unit was larger in the LI (0.46 ± 0.02) and the colon (0.44 ± 0.04) than that in the UI (0.12 ± 0.36; Figure [1](#jdi12681-fig-0001){ref-type="fig"}c). The density of L cells in the length of the crypt--villus was the highest in the colon (0.114 ±0.012 cells/μm), followed by the LI (0.073 ± 0.004 cells/μm) and then the UI (0.010 ± 0.002 cells/μm; Figure [1](#jdi12681-fig-0001){ref-type="fig"}d).

![The density and quality of L cells in the gastrointestinal (GI) tract of glucagon (Gcg)‐green fluorescent protein (GFP) knock‐in (Gcg‐GFP) heterozygous (Gcg^gfp/+^) mice. (a) Immunohistochemical images of the upper small intestine (UI), lower small intestine (LI) and colon of Gcg^gfp/+^ mice (bright field image and fluorescence image). (b) The length of the crypt--villus units in the UI,LI and colon was measured by immunohistochemistry (*n* = 5). (c) The number of GFP‐positive (+) cells per crypt--villus unit (*n* = 5). (d) The density of GFP(+) cells was normalized against the length of the crypt--villus unit (*n* = 5). (e) Glucagon‐like peptide‐1 (GLP‐1) content in GFP(+) cells and GFP(--) cells from the UI,LI and colon (*n* = 5). (f, g) The messenger ribonucleic acid expression levels of *Gcg* and *prohormone convertase* (*PC*) *1/3* in GFP(+) and GFP(--) cells from the UI,LI, and colon (*n* = 5). Expression levels were normalized against the internal control, *peptidylprolyl isomerase A* (*PPIA*). (h) GLP‐1 secretion from GFP(+) cells from the UI and LI (*n* = 3). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P *\< 0.001. NS, not significant.](JDI-9-25-g001){#jdi12681-fig-0001}

The GLP‐1 content in the L cells from the UI (1630 ± 224 pg/mL/protein), LI (487 ± 54 pg/mL/protein) and colon (684 ± 165 pg/mL/protein) was significantly higher than that in the non‐L cells of each part (Figure [1](#jdi12681-fig-0001){ref-type="fig"}e). Furthermore, the L cells from the UI contained approximately threefold more GLP‐1 compared with the L cells from the LI and colon (Figure [1](#jdi12681-fig-0001){ref-type="fig"}e). Because GLP‐1 is processed from the *proglucagon* gene[5](#jdi12681-bib-0005){ref-type="ref"}, GLP‐1 expression was assessed by the expression levels of *Gcg* mRNA. A set of primers for the *Gcg* mRNA was designed to span an exon--intron junction from exon 3 to exon 4. Neither GLP‐1 content nor *Gcg* mRNA was detected in non‐L cells of each part. The mRNA expression levels of *Gcg* were significantly higher in L cells than in non‐L cells of all parts of the GI tract (Figure [1](#jdi12681-fig-0001){ref-type="fig"}f). The mRNA expression levels of *Gcg* in L cells from the UI were 1.8‐fold higher than those in cells from the LI (Figure [1](#jdi12681-fig-0001){ref-type="fig"}f). GLP‐1 is produced in L cells through cleavage of proglucagon by PC1/3. The mRNA expression levels of *PC1/3* were significantly higher in L cells than those in non‐L cells in the UI, and tended to be higher in L cells than those in non‐L cells in the LI (Figure [1](#jdi12681-fig-0001){ref-type="fig"}g). The expression levels of *PC1/3* mRNA were very low in L cells from the colon. *PC2* mRNA was not detected in either L cells or non‐L cells from the UI, LI and colon (data not shown). GLP‐1 secretion in response to glucose stimulation was significantly higher in the L cells from the UI, compared with that in cells from the LI (Figure [1](#jdi12681-fig-0001){ref-type="fig"}h).

Expression levels of transcription factors in L cells {#jdi12681-sec-0016}
-----------------------------------------------------

We measured the mRNA expression levels of representative transcription factors in sorted L cells (Figure [2](#jdi12681-fig-0002){ref-type="fig"}). These transcription factors have been suggested to be expressed in L cells and other EECs. The expression levels of *islet 1* (*Isl1*) mRNA were significantly higher in L cells compared with those in non‐L cells from the UI and LI (Figure [2](#jdi12681-fig-0002){ref-type="fig"}b). Furthermore, L cells from the UI and LI showed significantly higher *Isl1* expression than L cells from the colon. L cells from the LI showed significantly higher expression of *Pax6* mRNA than L cells from the colon (Figure [2](#jdi12681-fig-0002){ref-type="fig"}c). The expression levels of *regulatory factor X 6* (*Rfx6*) mRNA in L cells from the UI were significantly higher than those in non‐L cells from the UI (Figure [2](#jdi12681-fig-0002){ref-type="fig"}e). Finally, there were no differences in the mRNA expression of *Pdx1* and *Pax4* between the L cells of each part (Figure [2](#jdi12681-fig-0002){ref-type="fig"}a,d).

![Expression of transcription factors in L cells. (a--e) The messenger ribonucleic acid expression levels of transcription factors in green fluorescent protein (GFP)‐positive (GFP\[+\]) cells and GFP‐negative (GFP\[--\]) cells from the upper small intestine (UI), lower small intestine (LI) and colon (*n* = 5). Expression levels were normalized against the internal control, *peptidylprolyl isomerase A* (*PPIA*). \**P *\<* *0.05, \*\**P *\<* *0.01, \*\*\**P *\<* *0.001. *Isl1*,*islet 1*;NS, not significant; *Pax4*,*paired box gene 4*;*Pax6*,*paired box gene 6*;*Pdx1*,*pancreatic duodenal homeobox 1*;*Rfx6*,*regulatory factor X 6*.](JDI-9-25-g002){#jdi12681-fig-0002}

Expression of other intestinal hormones in L cells {#jdi12681-sec-0017}
--------------------------------------------------

We next measured the content of another incretin peptide, GIP, and the mRNA expression levels of other enteroendocrine hormones in L cells (Figure [3](#jdi12681-fig-0003){ref-type="fig"}). In the UI, the GIP content in L cells was significantly higher than that in non‐L cells (Figure [3](#jdi12681-fig-0003){ref-type="fig"}a). Figure [3](#jdi12681-fig-0003){ref-type="fig"}a and b shows that expression levels of GIP protein parallel mRNA expression levels of *GIP* in L cells. The mRNA expression levels of *GIP* in L cells from the UI were significantly higher compared with those in cells from the LI and colon (Figure [3](#jdi12681-fig-0003){ref-type="fig"}b). The mRNA expression levels of *PYY*,*secretin* and *cholecystokinin* (*CCK*) were significantly higher in L cells than those in non‐L cells in all parts of the GI tract (Figure [3](#jdi12681-fig-0003){ref-type="fig"}c--e). The mRNA expression of *PYY* in L cells from the LI was higher than that in cells from the UI and colon (Figure [3](#jdi12681-fig-0003){ref-type="fig"}c). The expression of *secretin* mRNA in the L cells from the UI and LI was higher than that in cells from the colon (Figure [3](#jdi12681-fig-0003){ref-type="fig"}d). The expression levels of *CCK* mRNA in L cells were the highest in the UI, second highest in the LI and the lowest in the colon (Figure [3](#jdi12681-fig-0003){ref-type="fig"}e). *Somatostatin* mRNA was barely expressed in the L cells of each segment, similar to the case of non‐L cells (Figure [3](#jdi12681-fig-0003){ref-type="fig"}f).

![Expression of enteroendocrine hormones in L cells. (a) Gastric inhibitory polypeptide (GIP) content in GFP‐positive (GFP\[+\]) cells and GFP‐negative (GFP\[--\]) cells from the upper small intestine (UI), lower small intestine (LI), and colon (*n* = 5). (b--f) *GIP*,*peptide YY* (*PYY*), *secretin*,*cholecystokinin* (*CCK*) and *somatostatin* messenger ribonucleic acid levels in GFP(+) and GFP(--) cells from the UI,LI, and colon (*n* = 5). Expression levels were normalized against the internal control, *peptidylprolyl isomerase A* (*PPIA*). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. NS, not significant.](JDI-9-25-g003){#jdi12681-fig-0003}

Discussion {#jdi12681-sec-0018}
==========

In the present study, Gcg‐GFP mice expressing GFP under the control of the native *proglucagon* promoter enabled us to directly assess L cells, revealing quantitative and qualitative differences between L cells in the UI, LI, and colon. The present findings showed that the number of L cells increases from the UI to the colon, and that they have different expression patterns of transcription factors and hormones.

The classifications of EECs and hormones have historically relied on granule morphology and immunochemical studies[3](#jdi12681-bib-0003){ref-type="ref"}, [4](#jdi12681-bib-0004){ref-type="ref"}. The immunoreactivity technique has shown that L‐cells contain several hormones[4](#jdi12681-bib-0004){ref-type="ref"}, [13](#jdi12681-bib-0013){ref-type="ref"}. Although the specificity of antibodies has always been discussed, L cells have been shown to exist broadly in the GI tract and occur most often in the LI[5](#jdi12681-bib-0005){ref-type="ref"}. A recent report using fluorescently labeled L cells showed an increase in density from the duodenum to the colon[17](#jdi12681-bib-0017){ref-type="ref"}. Our results of the localization and the number of L cells using anti‐GFP antibody reactivity matched the findings of previous studies showing an increase in the number of L cells toward the colon[5](#jdi12681-bib-0005){ref-type="ref"}. Additionally, the function of the GI tract has been evaluated by the surface area, which differs in each part of the tract. Therefore, we measured the density of L cells as L cells/length of the crypt--villus unit to compensate for the different surface area of each part. Our study showed that the highest density of L cells throughout the GI was in the colon. In the present study, we used only adult male mice to evaluate the characteristics and distribution of L cells. The effect of aging and sex on the localization and density of primary L cells is yet unknown.

We also characterized L cells from the UI, LI and colon. The GLP‐1 content and expression levels of *Gcg* mRNA were higher in the UI compared with the LI and colon. Previous reports have shown lower expression levels of *Gcg* mRNA in L cells from the UI compared with the colon[11](#jdi12681-bib-0011){ref-type="ref"}, [17](#jdi12681-bib-0017){ref-type="ref"}. Conversely, recent reports have shown that L cells in the UI exhibit GLP‐1 secretion[12](#jdi12681-bib-0012){ref-type="ref"}. This discrepancy might stem from the differences between transgenic mice and our knock‐in mice. Thus, these data indicate that L cells exhibit differences not only in their numbers throughout the GI tract, but also in terms of molecular characteristics.

L cells secrete GLP‐1 into the circulation in response to various nutrients and neuromodulators. Whether the early postprandial GLP‐1 secretion originates from a few L cells in the UI or from L cells located further down the tract in the LI and colon is not clear. It has been suggested that a neural signal from the UI reaches L cells in the more distal intestine and colon[22](#jdi12681-bib-0022){ref-type="ref"}. The present data showed that GFP(+) L cells from the UI had the highest amount of GLP‐1 content, the highest expression levels of *Gcg* mRNA. Furthermore, an *ex vivo* GLP‐1 secretion experiment showed higher GLP‐1 secretion from L cells in the UI. Therefore, the small number of L cells in the UI might explain the capacity to activate early postprandial secretion of GLP‐1.

PC1/3 is an essential enzyme for producing GLP‐1 from proglucagon protein. Expression levels of *PC1/3* mRNA were increased in L cells of UI compared with those of LI, suggesting that GLP‐1 synthesis is increased in L cells of the UI. In contrast, *PC1/3* mRNA expression levels were extremely low, but GLP‐1 protein levels were detectable in L cells of the colon. It is unclear how much *PC1/3* mRNA expression level in L cells is required for PC1/3 enzymatic activity, but there would be a possibility that PC1/3 enzymatic activity in L cells is differently regulated depending on the distribution. Although we could not measure the PC1/3 enzymatic activity in L cells, further study is required to clarify the mechanism.

Studies using transcription factor‐deficient mice have indirectly confirmed the requirement of specific transcription factors in the development of the EEC lineage[23](#jdi12681-bib-0023){ref-type="ref"}, [24](#jdi12681-bib-0024){ref-type="ref"}, [25](#jdi12681-bib-0025){ref-type="ref"}. However, little is known about the expression of transcription factors in L cells. Although Pax6 has been shown to activate the *proglucagon* gene in L cells[15](#jdi12681-bib-0015){ref-type="ref"}, our data showed that *Pax6* was expressed in L cells and non‐L cells at the same level. We could not detect any transcription factor specific to L cells, even in L‐cells from the UI, which contained the highest amount of GLP‐1 (Figure [2](#jdi12681-fig-0002){ref-type="fig"}). Nevertheless, the present results revealed that *Isl1* showed significantly higher expression in L cells from the UI and LI. *Isl1* is a LIM‐homeodomain transcription factor that promotes islet cell proliferation[26](#jdi12681-bib-0026){ref-type="ref"}. Additionally, mice with intestinal epithelial‐specific deletion of *Isl1* showed loss of GLP‐1, GIP, CCK and somatostatin‐expressing cells, and impaired glucose homeostasis[27](#jdi12681-bib-0027){ref-type="ref"}. We found that *Isl1* was expressed at higher levels in L cells from the UI and LI. Isl1 might not only be involved in L cell development, but also in GLP‐1 synthesis; however, further experiments are required to clarify the role of *Isl1* in GLP‐1 expression. In Rfx6‐deficient mice, none of the endocrine cells, excluding pancreatic polypeptide‐expressing cells, were detected in the islets of these mice[28](#jdi12681-bib-0028){ref-type="ref"}. Here, we confirmed a notable mRNA expression of *Rfx6* and *GIP* in L cells from the UI. GIP is one other incretin secreted from K cells located in the duodenum and UI[29](#jdi12681-bib-0029){ref-type="ref"}. In our previous report[21](#jdi12681-bib-0021){ref-type="ref"}, we showed that Rfx6 plays critical roles in GIP expression, but not in GLP‐1 expression. Another report has shown that L cells in the UI are more similar to K cells in the UI than to L cells in the LI and colon[11](#jdi12681-bib-0011){ref-type="ref"}. Considering our results and these reports, we propose that Rfx6 induces GIP expression in L cells located in the UI, but further study is required.

The developmental relationships between EECs that arise from secretory precursors have been examined by genetically engineered mice[9](#jdi12681-bib-0009){ref-type="ref"}, [18](#jdi12681-bib-0018){ref-type="ref"}, [29](#jdi12681-bib-0029){ref-type="ref"}. The ablation of secretin‐producing cells decreased the number of L cells and CCK‐producing cells, suggesting that these cells are developmentally related[9](#jdi12681-bib-0009){ref-type="ref"}. Tissue‐specific post‐translational processing of proglucagon in L cells produces GLP‐1 and GLP‐2. Elimination of the *proglucagon* promoter resulted in reduction in GLP‐1, PYY, CCK, secretin and GIP[18](#jdi12681-bib-0018){ref-type="ref"}. These results suggest that EECs co‐express several kinds of functionally related hormones. Recent studies have shown that different EECs have more hormones than originally thought, and that the expression patterns of GI hormones depend on their localization[11](#jdi12681-bib-0011){ref-type="ref"}. L cells from Gcg‐GFP mice also expressed several GI hormones: PYY, GIP, secretin and CCK. We observed significant differences in the expression patterns of these GI hormones depending on their distribution. PYY has also been identified for its role in regulating appetite and bodyweight[30](#jdi12681-bib-0030){ref-type="ref"}. We observed a significant high expression of *PYY* in L cells from the LI. This result is consistent with that by Svendsen *et al*.[12](#jdi12681-bib-0012){ref-type="ref"}, who showed that PYY is secreted from L cells in the distal part of the intestine. CCK‐GFP mice have shown that CCK‐producing cells in the duodenum express Gcg, PYY, GIP and secretin[31](#jdi12681-bib-0031){ref-type="ref"}. Using specific genetically engineered Gcg‐GFP mice, we confirmed that L cells from the UI also express significantly high *CCK* and *secretin* mRNA.

In clinical practice, GLP‐1 secretion in patients with type 2 diabetes is impaired; however, the incretin effect of GLP‐1 is preserved[32](#jdi12681-bib-0032){ref-type="ref"}. Therefore, GLP‐1‐based therapies have been developed for patients with type 2 diabetes[5](#jdi12681-bib-0005){ref-type="ref"}, [6](#jdi12681-bib-0006){ref-type="ref"}, [7](#jdi12681-bib-0007){ref-type="ref"}. Recent investigations have shown that the increased plasma GLP‐1 concentration in patients with type 2 diabetes who underwent a gastric bypass or sleeve gastrectomy surgery normalized their blood glucose levels[7](#jdi12681-bib-0007){ref-type="ref"}, [33](#jdi12681-bib-0033){ref-type="ref"}. It has been reported that the possible mechanisms are that these surgeries lead to gut hypertrophy and an increase in the number of L cells in the LI, resulting in increased plasma GLP‐1 levels[34](#jdi12681-bib-0034){ref-type="ref"}, [35](#jdi12681-bib-0035){ref-type="ref"}. However, these kinds of surgery are greatly invasive and expensive. As we showed that L cells from the UI contain the highest amount of GLP‐1, a strategy for stimulating GLP‐1 exocytosis might be efficient for L cells in the UI. Additionally, increasing the number of L cells in the UI by promoting differentiation might enable patients to significantly elevate their plasma GLP‐1 levels. The present results suggest the therapeutic potential of promoting GLP‐1 release from L cells for the treatment of type 2 diabetes; however, further research is required.

In conclusion, using Gcg‐GFP mice as an L cell reporter model, we clearly showed that L cells exhibit different numbers and characteristics depending on their distribution in the gut. L cells also express different levels of gut hormones and transcription factors' mRNA.
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